ArticleInternational journal of surgery case reports2026
Intraductal papillary mucinous neoplasm with pseudomyxoma peritonei: a case report.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pseudomyxoma peritonei (PMP) secondary to pancreatic intraductal papillary mucinous neoplasms (IPMNs) is extremely rare, making diagnosis and treatment of this condition challenging. Case presentation: We present a case of a 67-year-old gentleman diagnosed with a malignant degeneration of IPMN, treated with neoadjuvant systemic therapy, followed by total pancreatectomy. Twelve months after his surgery, he was found to have two capsular hepatic lesions on surveillance imaging. Biopsy confirmed pseudomyxoma peritonei, and the patient subsequently underwent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Discussion: This unique case highlights the importance of post-operative surveillance for surgically resected IPMNs and understanding the role for CRS and HIPEC as an option for treating PMP secondary to IPMNs. Conclusion: Although PMP secondary to IPMN is extremely uncommon, it can occur months to years after initial surgery, and for patients in whom complete cytoreduction is achievable, CRS and HIPEC may represent a viable treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.